Borderline rejection in ABO-incompatible kidney transplantation

• Published in: Clinical transplantation 2016-08, Vol.30 (8), p.872-879
• Main Authors: Sánchez-Escuredo, Anna, Oppenheimer, Federico, Solé, Manel, Revuelta, Ignacio, Cid, Joan, Lozano, Miguell, Blasco, Miquel, Esforzado, Nuria, Ricart, Maria Jose, Cofán, Federico, Torregrosa, Josep Vicens, Paredes, David, Musquera, Mireia, Ercilla, Guadalupe, Campistol, Josep M., Diekmann, Fritz
• Format: Article
• Language: English
• Subjects: ABO Blood-Group System - immunology; ABOi transplant; Adult; Aged; Biopsy; Blood Group Incompatibility - complications; Blood Group Incompatibility - immunology; borderline rejection; Female; Follow-Up Studies; Graft Rejection - diagnosis; Graft Rejection - etiology; Graft Rejection - immunology; Graft Survival; Humans; Kidney Transplantation - adverse effects; Living Donors; Male; Middle Aged; Prospective Studies; protocol biopsies; Transplant Recipients; Young Adult
• ISSN: 0902-0063; 1399-0012
• DOI: 10.1111/ctr.12759

Introduction The clinical results of ABO‐incompatible (ABOi) and ABO‐compatible (ABOc) kidney transplantation (KT) are similar. Protocol kidney biopsies (PKB) of ABOi transplant recipients show positivity for C4d without evidence of antibody‐mediated rejection (ABMR), but little is known about the histologic progression. Method We evaluated histologic parameters in PKB at 12 months and also compared clinical outcome at 1 year. This is a prospective observational study conducted between 2009 and 2013. We performed 146/30 ABOc/ABOi consecutive living‐donor KT with PKB as well as additional indication biopsies. In the ABOi group, the desensitization protocol consisted of rituximab, plasma exchange or immunoadsorption, and immunoglobulins. Results In indication biopsies during the first year, T‐cell‐mediated rejection Banff ≥immunoadsorption was 8.2% vs 6.7% (P=.561) and ABMR 4.8% vs 13.3% (P=.095). At 1 year, PKB (ABOc/ABOi) showed differences in borderline rejection lesions (6.8% vs 23.3% [P=.012]) and in C4d positivity in the ABOi group (P=.001). Interstitial fibrosis and tubular atrophy (IFTA) lesions (ABOc/ABOi) were 68.4% vs 63.2% (P=.348). Transplant glomerulopathy was 0.7% vs 3.3% (P=.373) at 1 year. Conclusions Our PKB ABOi series shows at 1 year more borderline lesions independent of ABO titers, HLA incompatibility, and the presence of antidonor antibody, but do not show more IFTA nor transplant glomerulopathy. No clinical differences were observed between ABOi and ABO transplants.